triple-hormone-receptor agonist retatrutide for obesity Triple Agonism Based Therapies Retatrutide: FDA approval time, trial

bit.ly/4fcDSzJ @AHAScience #AHAJournals

53 Generally, the reported K m of PARP1 and CD38 for NAD + are lower than those of the sirtuins, suggesting that elevated activation of PARP1 or CD38 may limit endogenous SIRT activation by reducing NAD + content

Indeed, GH-replacement therapy, as well as treatment with rhIGF-1, increased serum calcitriol levels in GH-deficient patients [145, 146]

We recommend that patients maintain the current dose, or lower the dose until symptoms resolve

In Figure6B we scale our units so they are 2 at dose of 833 mg/kg so they correspond numerically to the values given by Mitchell et al.[6] and are more easily compared